Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer
-
Published:2023-02-24
Issue:1
Volume:13
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Wang Lucy,Evans James C.,Ahmed Lubabah,Allen Christine
Abstract
AbstractCombination chemotherapy is an established approach used to manage toxicities while eliciting an enhanced therapeutic response. Delivery of drug combinations at specific molar ratios has been considered a means to achieve synergistic effects resulting in improvements in efficacy while minimizing dose related adverse drug reactions. The benefits of this approach have been realized with the FDA approval of Vyxeos®, the first liposome formulation to deliver a synergistic drug combination leading to improved overall survival against standard of care. In the current study, we demonstrate the synergistic potential of the PARP inhibitor niraparib and doxorubicin for the treatment of ovarian cancer. Through in vitro screening in a panel of ovarian cancer cell lines, we find that niraparib and doxorubicin demonstrate consistent synergy/additivity at the majority of evaluated molar ratio combinations. Further to these findings, we report formulation of a nanoparticle encapsulating our identified synergistic combination. We describe a rational design process to achieve highly stable liposomes that are targeted with folate to folate-receptor-alpha, which is known to be overexpressed on the surface of ovarian cancer cells. With this approach, we aim to achieve targeted delivery of niraparib and doxorubicin at a pre-determined synergistic molar ratio via increased receptor-mediated endocytosis.
Funder
U.S. Department of Defense
NanoMedicines Innovation Network
Natural Sciences and Engineering Research Council of Canada
Centre for Pharmaceutical Oncology
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference57 articles.
1. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2021, Can. Cancer Soc. Stat. Canada Public Heal. Agency Canada (2021) 1–95.
2. The American Cancer Society. Key Statistics for Ovarian Cancer. Am. Cancer Soc. (2022) 1. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html.
3. NIH National Cancer Institute. Cancer Stat Facts: Ovarian Cancer (2022). https://seer.cancer.gov/statfacts/html/ovary.html.
4. Kim, G. et al. FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 21, 4257–4261. https://doi.org/10.1158/1078-0432.CCR-15-0887 (2015).
5. AstraZenica, Lynparza Monograph, 2022.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献